Equity · Healthcare

PROF

Profound Medical Corp. · NasdaqCM

$6.66 −5.74% 1D Finazon · prior-day close

Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for PROF to draw a line in its place.

The chart above plots the price of PROF over the range selected — one day to the full history — drawn by TradingView from their own data.

Market cap $243.1M

52-week range $4 – $8.69

Avg volume 18.2K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 21, 2026

About Profound Medical Corp.

Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free ablation therapies for diseased tissue. Its main product, the TULSA-PRO system, is used for the ablation of malignant or benign prostate tissue and is cleared or approved for use in the United States, European Union, and Canada. The company also offers the Sonalleve system, which is CE Marked in the EU and approved in China, South Korea, and the United States for the ablation of uterine fibroids, adenomyotic tissue, pain relief from bone metastases, treatment of osteoid osteoma, and management of benign desmoid tumors.

Company

Exchange NasdaqCM

Sector Healthcare

Class Equity

Filings 3 sets

PROF earnings

SEC EDGAR

Date Period EPS Revenue

30 Jun 2026 Q2 2026 $-0.26 $2M

31 Mar 2026 Q1 2026 $0.19 $5M

31 Dec 2025 FY 2025 $1.41 $16M

30 Sep 2025 Q3 2025 $0.26 $5M

30 Jun 2025 Q2 2025 $-0.52 $2M

31 Mar 2025 Q1 2025 $0.36 $3M

31 Dec 2024 FY 2024 $1.12 $11M

30 Sep 2024 Q3 2025 $0.38 $3M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

PROF

Filings 3 sets

PROF reported financials

PROF earnings

PROF institutional holders